Delta細胞癌症治療市場規模、佔有率和成長分析：按療法、改良狀態、癌症適應症、癌症分期、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Delta T 細胞癌症治療市場價值為 14.8 億美元，預計到 2025 年將成長至 16.5 億美元，到 2033 年將成長至 39.4 億美元，在預測期（2026-2033 年）內複合年成長率為 11.5%。

全球Delta細胞癌症治療市場是一個充滿活力的領域，專注於利用γδT淋巴細胞的獨特特性，開發創新細胞免疫療法，以有效治療多種癌症。 γδT細胞具有辨識壓力誘導抗原的獨特能力，且不受組織相容性限制，與傳統的CAR-T療法相比，具有更高的安全性。由於生產平台的進步和新型γδT細胞產品線的出現，提高了生產效率並改善了患者的治療機會，該市場正在快速擴張。各公司也正在開發即用型（現成）療法，以加快臨床實驗的入組速度。此外，人工智慧（AI）透過最佳化標靶發現和改進臨床試驗設計，加速了研發進程，最終縮短了研發週期並降低了成本。隨著療效證據的不斷增強，在臨床應用範圍擴大和醫保報銷前景改善的推動下，該市場預計將顯著成長。

全球Delta細胞癌症治療市場的成長要素

全球Delta細胞癌症療法市場正受益於令人矚目的臨床試驗結果，這些結果凸顯了其療效和安全性，增強了腫瘤學家和投資者的信心。隨著相關證據的積累，治療方案的採納範圍不斷擴大，研究經費也隨之增加。醫療專業人員越來越依賴免疫療法，因為他們親眼目睹了患者病情的顯著改善，這促使製藥公司加強對開發平臺的投資。此外，醫療機構正在投入資源提供專門的治療，這進一步推動了市場成長，並鞏固了Delta細胞療法在腫瘤治療領域的地位。這些正面成果也促進了學術機構和私人企業之間的合作。

全球Delta細胞癌症治療市場的限制因素

全球Delta細胞癌症療法市場面臨許多挑戰，這些挑戰主要源自於其複雜精細的生產流程。 γδT細胞療法的生產需要嚴格的細胞分離、增殖和基因改造，所有這些步驟都必須在嚴格的無菌條件下進行，以確保安全性和有效性。這些嚴苛的要求不僅增加了生產流程的複雜性，也推高了營運成本，可能阻礙該療法的市場擴充性和普及。因此，這些因素可能會阻礙Delta細胞療法領域的整體成長和發展。

全球Delta細胞癌症治療市場趨勢

受基因測序技術進步的推動，全球Delta細胞癌症治療市場正呈現出對個人化新抗原標靶化的顯著趨勢。這種創新方法使製造商能夠開發針對個別患者新抗原的客製化療法，從而顯著提高治療精準度並最大限度地減少脫靶效應。因此，投資者對利用這一潛力的興趣日益濃厚，與專業實驗室的合作也日益增加。此外，數據儲存庫的擴展使得快速識別最佳抗原組合成為可能，從而簡化了臨床試驗的患者招募和監管流程。這些進步正在改變商業格局，使個人化Delta細胞療法成為全球腫瘤學領域極具吸引力的成長動力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Delta細胞癌症治療市場規模：依治療方法分類

• 同種異體Delta細胞療法
• 自體Delta細胞療法

全球Delta細胞癌症療法市場規模：依改良狀態分類

• 基因改造的Delta細胞
  • CAR- Delta細胞
  • TCR增強的Delta細胞
• 未修飾的Delta細胞

全球Delta細胞癌症治療市場規模：以癌症適應症分類

• 骨髓惡性腫瘤
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
• 固體癌
  • 膠質母細胞瘤
  • 胰臟癌
  • 結腸癌
  • 其他

全球Delta細胞癌症治療市場規模：依癌症分期分類

• 早期的
• 晚期
• 復發性癌症
• 難治性癌症

全球Delta細胞癌症療法市場規模：依作用機制分類

• T細胞活化
• 抑制腫瘤微環境
• 標靶化腫瘤抗原
• 增強免疫查核點抑制

全球Delta細胞癌症療法市場規模：以最終用戶分類

• 大學附屬癌症中心
• 專科腫瘤醫院
• 合約研究機構
• 臨床試驗設施
• 高階細胞治療網路

全球Delta細胞癌症療法市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Adicet Bio Inc.
• LAVA Therapeutics NV
• TC BioPharm Holdings PLC
• Adaptate Biotherapeutics Limited
• Gadeta BV
• In8bio Inc.
• Arovella Therapeutics Limited
• Immatics NV
• Takeda Pharmaceutical Company Limited
• PhosphoGam SAS
• GammaDelta Therapeutics Limited
• Senda Biosciences Inc.
• American Gene Technologies International Inc.
• Trikon Clinical Therapeutics
• Century Therapeutics Inc.
• GamaMabs Pharma SA
• Kiromic BioPharma Inc.
• Sandhill Therapeutics Inc.
• Bio-Innova Co. Ltd.
• Delta-Fly Pharma Inc

結論與建議

Global Gamma Delta T Cell Cancer Therapy Market size was valued at USD 1.48 Billion in 2024 and is poised to grow from USD 1.65 Billion in 2025 to USD 3.94 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The global gamma-delta T-cell cancer therapy market represents a dynamic sector focused on innovative cellular immunotherapies utilizing the unique properties of Yδ T lymphocytes to effectively combat various cancers. The distinct capability of Yδ cells to identify stress-induced antigens without histocompatibility restrictions offers safety advantages compared to traditional CAR-T therapies. The market's value has surged, driven by enhanced manufacturing platforms and emerging Yδ cell pipelines that streamline production and increase patient access. Companies are also developing off-the-shelf treatments to facilitate faster trial enrollment. Moreover, artificial intelligence is accelerating advancements by optimizing target discovery and improving trial design, ultimately shortening development timelines and reducing costs. As validation strengthens, the market anticipates substantial growth, propelled by expanded clinical applications and improved reimbursement prospects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gamma Delta T Cell Cancer Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gamma Delta T Cell Cancer Therapy Market Segments Analysis

Global gamma delta t cell cancer therapy market is segmented by therapy type, modification state, cancer indication, stage of cancer, mechanism of action, end user and region. Based on therapy type, the market is segmented into Allogeneic Gamma Delta T Cell Therapies and Autologous Gamma Delta T Cell Therapies. Based on modification state, the market is segmented into Genetically Modified Gamma Delta T Cells and Unmodified Gamma Delta T Cells. Based on cancer indication, the market is segmented into Hematologic Malignancies and Solid Tumors. Based on stage of cancer, the market is segmented into Early Stage, Advanced Stage, Relapsed Cancer and Refractory Cancer. Based on mechanism of action, the market is segmented into Activation of T Cells, Inhibition of Tumor Microenvironment, Targeting Tumor Antigens and Enhancing Immune Checkpoint Inhibition. Based on end user, the market is segmented into Academic Cancer Centers, Specialty Oncology Hospitals, Contract Research Centers, Clinical Trial Centers and Advanced Cell Therapy Treatment Networks. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gamma Delta T Cell Cancer Therapy Market

The Global Gamma Delta T Cell Cancer Therapy market is positively influenced by impressive clinical trial results highlighting both efficacy and safety, instilling confidence in oncologists and investors alike. This accumulating evidence promotes broader adoption within treatment protocols and fuels increased research funding. As healthcare professionals witness significant patient improvements, there is a trend toward greater reliance on immunotherapy options, leading pharmaceutical companies to invest more in their development pipelines. Additionally, healthcare institutions are dedicating resources for specialized treatment delivery, collectively propelling market growth while solidifying the role of gamma delta T cell therapies within oncology. The favorable outcomes also encourage collaboration between academic institutions and commercial entities.

Restraints in the Global Gamma Delta T Cell Cancer Therapy Market

The Global Gamma Delta T Cell Cancer Therapy market faces significant challenges related to the complex and meticulous processes involved in manufacturing these therapies. The production of gamma delta T cell therapies demands exacting cell isolation, expansion, and genetic modification, all of which must be performed under strict aseptic conditions to ensure safety and efficacy. These stringent requirements not only complicate the manufacturing process but also elevate operational costs, which can hinder the scalability and accessibility of such therapies in the market. Consequently, these factors can impede the overall growth and development of the gamma delta T cell therapy landscape.

Market Trends of the Global Gamma Delta T Cell Cancer Therapy Market

The Global Gamma Delta T Cell Cancer Therapy market is witnessing a notable trend towards personalized neoantigen targeting, driven by advancements in genomic sequencing technologies. This innovative approach allows manufacturers to develop therapies tailored to individual patient neoantigens, significantly enhancing therapeutic precision while minimizing off-target effects. As a result, there is increased investor interest and collaborations with specialty laboratories to harness this potential. Additionally, the expansion of data repositories facilitates rapid identification of optimal antigen panels, streamlining trial enrollments and regulatory processes. This evolution is reshaping the commercial landscape, positioning personalized gamma-delta T cell therapies as a compelling growth vector within global oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gamma Delta T Cell Cancer Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Allogeneic Gamma Delta T Cell Therapies
• Autologous Gamma Delta T Cell Therapies

Global Gamma Delta T Cell Cancer Therapy Market Size by Modification State & CAGR (2026-2033)

• Market Overview
• Genetically Modified Gamma Delta T Cells
  • CAR-Gamma Delta T Cells
  • TCR-Enhanced Gamma Delta T Cells
• Unmodified Gamma Delta T Cells

Global Gamma Delta T Cell Cancer Therapy Market Size by Cancer Indication & CAGR (2026-2033)

• Market Overview
• Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Solid Tumors
  • Glioblastoma
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

Global Gamma Delta T Cell Cancer Therapy Market Size by Stage of Cancer & CAGR (2026-2033)

• Market Overview
• Early Stage
• Advanced Stage
• Relapsed Cancer
• Refractory Cancer

Global Gamma Delta T Cell Cancer Therapy Market Size by Mechanism of Action & CAGR (2026-2033)

• Market Overview
• Activation of T Cells
• Inhibition of Tumor Microenvironment
• Targeting Tumor Antigens
• Enhancing Immune Checkpoint Inhibition

Global Gamma Delta T Cell Cancer Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Academic Cancer Centers
• Specialty Oncology Hospitals
• Contract Research Centers
• Clinical Trial Centers
• Advanced Cell Therapy Treatment Networks

Global Gamma Delta T Cell Cancer Therapy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Modification State, Cancer Indication, Stage of Cancer, Mechanism of Action, End User)
  • US
  • Canada
• Europe (Therapy Type, Modification State, Cancer Indication, Stage of Cancer, Mechanism of Action, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modification State, Cancer Indication, Stage of Cancer, Mechanism of Action, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modification State, Cancer Indication, Stage of Cancer, Mechanism of Action, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modification State, Cancer Indication, Stage of Cancer, Mechanism of Action, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Adicet Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LAVA Therapeutics N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TC BioPharm Holdings PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptate Biotherapeutics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gadeta BV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• In8bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arovella Therapeutics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhosphoGam SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GammaDelta Therapeutics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senda Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• American Gene Technologies International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trikon Clinical Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Century Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GamaMabs Pharma SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiromic BioPharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandhill Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Innova Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delta-Fly Pharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations